SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
11 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
10 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors,...
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
07 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
06 juin 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
22 mai 2024 08h30 HE
|
SeaStar Medical Holding Corporation
SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE...
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
14 mai 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
30 avr. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
17 avr. 2024 16h00 HE
|
SeaStar Medical Holding Corporation
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
11 avr. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...